The Venture Codex Logo

The Venture Codex

Radix

Aleja Armii Ludowej 26, Warszawa, Mazowieckie, 00-609, Polska

Overview

Established in 2024 by experienced entrepreneurs and tech investors we are on the mission to empower deep tech innovators across Europe.

Total investments
3
Lead investments
1
Investments · 12mo
2
Active investors
1

Sector focus

  • Venture Capital
Visit website

Investment portfolio

  • Healant

    Led · Equity · Jul 2026

    Healant is a Belgian deeptech spin-off from Vrije Universiteit Brussel that develops a self-healing polymer layer designed to automatically seal tire punctures, extending tire life and reducing downtime, costs and material waste. The company is led by founder and CEO Simon Beckers. Its technology targets mobility and industrial tire applications with a focus on scalability and sustainability. The recent €4 million financing is intended to enable a commercial launch, scale production processes, refine the go-to-market strategy, and establish strategic partnerships. The article does not disclose revenue, user counts, founding year, or prior funding history.

  • Proteine Resources

    Participated · Equity · Nov 2025

    Founded in 2018 by Konrad Włodarczyk and Bartłomiej Roszkowski, Proteine Resources converts mushroom-industry by-products into high-value, insect-based proteins and bioactive compounds for pet food, veterinary supplements, animal feed, cosmetics, and pharmaceuticals. Its patented technology platform, paired with an AI-driven automation system, supports fully autonomous, low-staff factories that operate with zero waste, high energy efficiency, and a carbon-negative footprint. The resulting EntoPro™ protein is hypoallergenic and matches beef-level quality while remaining more sustainable. The company’s modular production units enable decentralized, location-flexible manufacturing, positioning the business for rapid global roll-out. With fresh capital, Proteine Resources plans to scale its pilot site in the Mazowieckie region tenfold to 100 tons of annual output and construct what it claims will be the world’s first fully autonomous insect-protein facility. Additional resources will advance clinical trials to substantiate health claims, develop gut-health formulations, and support market entry across Europe. Including its most recent round, the firm has secured nearly €12 million to date.

  • Fluence Technology

    Participated · Seed · Aug 2025

    Fluence Technology produces compact, shock‑resistant, fibre-based femtosecond lasers with a nearly zero failure rate in their key pulse source, delivering maintenance‑free performance previously limited to research labs. Its systems are used by leading electronics manufacturers in East Asia and the United States for applications such as microvias, micromachining of silicon, gallium nitride and silicon carbide, interposers, photonic components, micro‑LED displays, consumer electronics parts, and medical devices. The company was founded by four Polish physicists and is led by CEO Dr. Michał Nejbauer. Fluence says its lasers enable higher precision and reliability needed for advanced chip and semiconductor manufacturing and other emerging applications. The company plans to accelerate international expansion, scale its business, and broaden application areas including security, space, and military uses. Financially, Fluence recently closed a seed round to fund that international growth and technology development.

Team